January 21, 2015 By Riley McDermid , BioSpace.com Breaking News Sr. Editor Biopharma behemoth Merck & Co. ( MRK ) will discontinue selling its hepatitis C treatment Victrelis, the company told the U.S. Food and Drug administration this ... ClinicSpace, 1 day ago
Merck & Co drops marketing of hepatitis C drug Victrelis in USA - Pharma Letter, 3 days ago
Merck & Co updates on plans to accelerate new drug submissions and future growth - Pharma Letter, 1 week ago
Wei L, Lok AS. Impact of new hepatitis C treatments in different regions of the world. Gastroenterology 146(5), 11451150.e11411144 (2014). Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a ...General Medicine eJournal, 4 days ago
Facebook Twitter Google + Email Print The pharmaceutical company, Merck, has announced that they will stop the manufacture and distribution of their hepatitis C (HCV) protease inhibitor Victrelis by December 2015. As the landscape of HCV ...Project Inform, 4 days ago
Next generation commercial drones achieve a complete replacement of existing commercial airfreight delivery systems, they are used for 3D mapping, commercial pipeline observation, border patrol, package delivery, photography, and agriculture are ...Electronics.ca Publications, 1 week ago Commercial Drones: Highways in the Sky, Unmanned Aerial Systems (UAS), Market Shares, Strategies, and Forecasts, Worldwide, 2015 to 2021 Research and Markets, 1 week ago
Arguably no biotech stock thrilled investors in 2014 more than Gilead Sciences ( NASDAQ: GILD ) . Gilead finished the year up 26%, about double the performance of the broad-market indexes, and the approval and exceptional launch of hepatitis C ...Motley Fool, 2 weeks ago The Hepatitis C Drug Developer That Crushed Gilead Sciences, Inc. in 2014 (Hint: It's Not AbbVie) Motley Fool, 1 month ago Sovaldi Can't Sustain The Current Prices Of Gilead Sciences' Stock: Algorithmic And Fundamental Analysis Seeking Alpha, 1 month ago
Federal Awards Amatruda, James, Children's Hospital of Philadelphia/NIH, COG Solid Malignancy Integrated Translational Science Center Grant, $13,177; Aquino, Victor, Natl Childhood Cancer Fdn/NIH, Primary Immune Deficiency Treatment Consortium - ...University of Texas, 2 weeks ago
MERCK : Studies from Merck & Company Update Current Data on Hepatitis C Virus (Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined...
Studies from Merck & Company Update Current Data on Hepatitis C Virus (Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 ...) ...4 Traders, 2 weeks ago
The impact of specialty drugs continues to increase in both drug utilization and spend. In 2012, specialty drug spend accounted for approximately $87 billion, or about 3.1% of national health spend in the United States. In 2020, the forecasted ...Pharmacist.com, 3 weeks ago
GILD data by YCharts Despite last weeks' oil-induced swoon, the S&P 500 is still up by 8% for the year. But don't bother bragging about this to Gilead Sciences shareholders -- through the weekend, Gilead shares had nearly quintupled the broader ...Nasdaq, 1 month ago
Bourlière M, Sulkowski MS, Omata M, et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without RBV. Program and abstracts of the 65th annual meeting of the ...General Medicine eJournal, 1 month ago
on your WebpageAdd Widget >Get your members hooked!